<DOC>
	<DOCNO>NCT00837356</DOCNO>
	<brief_summary>This trial conduct Europe Asia . The aim clinical trial compare two recombinant factor VIII drug , turoctocog alfa ( recombinant factor VIII ( N8 ) ) Advate® , haemophilia A subject , investigate action safety drug .</brief_summary>
	<brief_title>Comparison Action Drugs Body Safety N8 Advate® Haemophilia A Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe haemophilia A ( FVIII level less equal 1 % ) Treatment history 150 exposure day recombinant plasmaderived FVIII replacement product HIV HCV negative , positive patient stable antiviral regimen time enrolment trial Presence bleeding disorder addition haemophilia A Inhibitor titre great equal 0.6 Bethesda Units ( BU ) screen past history inhibitor Abnormal renal function test Known hypersensitivity Advate®</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>